Picture loading failed.

Anti-TACSTD2 therapeutic antibody (Pre-made Datopotamab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Datopotamab deruxtecan is an antibody drug conjugate (ADC), composed of an humanised anti-TROP2 monoclonal antibody and MAAA 1181a, a derivative of exatecan, a DNA topoisomerase I inhibitor, being developed by Daiichi Sankyo for the treatment of solid tumours including non-small cell lung cancer and breast cancer .

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-134-1mg 1mg 3090
GMP-Bios-ab-134-10mg 10mg 21890
GMP-Bios-ab-134-100mg 100mg 148000
GMP-Bios-ab-134-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-TACSTD2 therapeutic antibody (Pre-made Datopotamab biosimilar,Whole mAb)
INN Name Datopotamab
TargetTACSTD2
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesDaiichi Sankyo
Conditions Approvedna
Conditions ActiveBreast cancer;Non-small cell lung cancer
Conditions Discontinuedna
Development Techna